At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 208 enrolled
Drug / intervention
Botulinum toxin A "BoNT/A-DP" +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blinded, Randomized, Controlled Study to Compare the Efficacy, Time to Onset, and Duration of Effect of Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines
In Brief
A Phase 2 clinical trial evaluating Botulinum toxin A "BoNT/A-DP" and Botulinum toxin A "Botox Cosmetics" for Frown Lines. Completed, enrolled 208 participants across 5 sites in 3 countries.
Detailed Summary
The purpose of the study is to provide preliminary comparative data on BoNT/A-DP versus Botox Cosmetic. Subsequently the sample size is primarily based on clinical judgement and practical considerations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFrown Lines
CountriesAustria, Canada, United States
CollaboratorsHugel
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartJun 2020
Primary CompletionNov 2020
Study CompletionFeb 2021
First PostedFeb 2021
TodayJul 2026
First PostedFeb 21, 2021
Enrollment StartJun 24, 2020
Primary CompletionNov 5, 2020
Study CompletionFeb 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.4 years ago
Interventions
Botulinum toxin A "BoNT/A-DP"biological
To assess the efficacy of treatment with BoNT/A-DP in reducing the severity of glabellar frown lines at maximum frown.
Botulinum toxin A "Botox Cosmetics"biological
To assess the efficacy of treatment with Botox Cosmetics in reducing the severity of glabellar frown lines at maximum frown.